Advertisement
Dr. Hung will provide an overview of Medivation and its clinicaldevelopment programs for Dimebon(TM) for Alzheimer's and Huntington's diseasesand MDV3100 for prostate cancer.
Advertisement
The Company reported results from its Phase 2 efficacy study of Dimebon inAlzheimer's disease in June 2007, demonstrating that Dimebon maintainedstatistically significant benefit over placebo on all five efficacy endpointsafter one year of therapy. Further, Dimebon patients were stabilized over theone-year study period, meaning that their level of function was preserved fora full year on all five endpoints.
A live audio webcast of each presentation will be available on the "Eventsand Presentations" page of the "Investor Relations" section of the Company'swebsite at http://www.medivation.com. A replay will also be available for 30days following the live presentation.
About Medivation
Medivation, Inc. is a biopharmaceutical company that acquires promisingtechnologies in the late preclinical development phase and develops themquickly and cost-effectively. Medivation's current portfolio consists of smallmolecule drugs in clinical development to treat three large, unmet medicalneeds -- Alzheimer's disease, Huntington's disease and hormone-refractoryprostate cancer. The Company intends to build and maintain a portfolio of fourto six development programs at all times. For more information, please go tohttp://www.medivation.com.-- ThinkEquity Partners' G5: The Fifth Annual Growth Conference on Monday, September 17, at 11:00 Pacific time at the St. Regis Hotel in San Francisco. -- The Maxim Group Growth Conference on Thursday, September 20, at 9:30 a.m. Eastern time at the Grand Hyatt Hotel in New York. -- The UBS 2007 Global Life Sciences Conference on Monday, September 24, at 8:30 a.m. Eastern time at the Grand Hyatt Hotel in New York.
SOURCE Medivation, Inc.
